Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 12/20 | 0.38 |
| ▸ | BTK | Q06187 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22970007 | 1.00 | CHRM1 (0.42) | CHRM1JAK3BTK | |
| SCHEMBL22704583 | 1.00 | CHRM1 (0.42) | CHRM1JAK3BTK | |
| SCHEMBL25976504 | 0.83 | TEAD1 (0.38) | JAK3BTK | |
| SCHEMBL20334409 | 0.81 | JAK3 (0.33) | JAK3BTK | |
| SCHEMBL21186659 | 0.81 | CHRM1 (0.36) | CHRM1 | |
| SCHEMBL25976400 | 0.80 | JAK3 (0.38) | CHRM1JAK3BTK | |
| SCHEMBL23664821 | 0.79 | JAK3 (0.34) | JAK3BTK | |
| SCHEMBL21186658 | 0.79 | JAK3 (0.34) | JAK3BTK | |
| SCHEMBL22970055 | 0.79 | JAK3 (0.34) | JAK3BTK | |
| SCHEMBL23735765 | 0.79 | TET3 (0.34) | JAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655248-B2 | Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655248-B2 | Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11453667-B2 | Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2022-09-27 | — | — | US | disclosed |
| WO-2022111521-A1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州多域生物技术有限公司 | 2022-06-02 | — | — | WO | disclosed |
| US-20210371411-A1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3842433-A1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | Medshine Discovery Inc. (CN) | 2021-06-30 | — | — | EP | disclosed |
| US-20210147418-A1 | Pyridone-Pyrimidine Derivative Acting As KRASG12C Mutein Inhibitor | MEDSHINE DISCOVERY INC (CN) | 2021-05-20 | — | — | US | disclosed |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2021-01-14 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
| EP-2970163-B1 | 5-THIAZOLECARBOXAMIDE DERVATIVES AND THEIR USE AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | CHRM1 4864/4885JAK3 3209/4885BTK 3723/4885 |
| US-11453667-B2 | Pyridone-pyrimidine derivative acting as KRASG12C mutein inhibitor | KRAS, NRAS, MSH2 | CHRM1 4719/4885JAK3 499/4885BTK 2069/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CHRM1 4864/4885JAK3 3209/4885BTK 3723/4885 |
| US-11655248-B2 | Pyridone-pyrimidine derivative acting as KRAS G12C mutein inhibitor | KRAS, NRAS, MSH2 | CHRM1 4653/4885JAK3 885/4885BTK 2256/4885 |
| US-20210009577-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | CHRM1 4864/4885JAK3 3209/4885BTK 3723/4885 |
| US-20210147418-A1 | Pyridone-Pyrimidine Derivative Acting As KRASG12C Mutein Inhibitor | KRAS, NRAS, MSH2 | CHRM1 4719/4885JAK3 499/4885BTK 2069/4885 |
| US-20210371411-A1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | KRAS, NRAS, MSH2 | CHRM1 4719/4885JAK3 499/4885BTK 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.